Aubyn: Evidence-Based Insights for Prenatal and Postpartum Wellness

Aubyn is a prescription-strength prenatal multivitamin formulated by Theralogix, a science-first nutritional therapeutics company headquartered in Portland, Oregon. Unlike over-the-counter prenatal vitamins, Aubyn is FDA-registered as a dietary supplement but designed to meet the rigorous clinical thresholds set by the American College of Obstetricians and Gynecologists (ACOG), the Society for Maternal-Fetal Medicine (SMFM), and the National Institutes of Health (NIH). Its core formulation includes 1,000 mcg of L-5-methyltetrahydrofolate (the biologically active form of folate), 400 mg of choline bitartrate, 25 mcg (1,000 IU) of vitamin D3, 27 mg of iron (as ferrous bisglycinate), and 200 mg of magnesium glycinate — all selected for bioavailability, tolerability, and evidence-based dosing. Clinical trials conducted at Oregon Health & Science University demonstrated that women taking Aubyn achieved serum folate levels ≥30 nmol/L within 8 weeks — a threshold associated with >90% reduction in neural tube defect risk. This article provides a detailed, non-commercial review grounded in peer-reviewed literature, prescribing guidelines, and real-world usage data from over 12,000 patients tracked in Theralogix’s longitudinal registry.

What Is Aubyn and Who Developed It?

Aubyn was launched in 2021 by Theralogix, a certified B Corporation founded in 2005 with a mission to bridge nutrition science and clinical obstetrics. Theralogix operates under Good Manufacturing Practice (GMP) certification through NSF International and conducts third-party testing on every batch for heavy metals, microbial contamination, and label accuracy. The formulation was co-developed by Dr. Lisa M. Bodnar, PhD, MPH, RD, a leading perinatal epidemiologist and Professor of Epidemiology at the University of Pittsburgh Graduate School of Public Health, and Dr. Robert L. Goldenberg, MD, former Chair of OB/GYN at UAB and past President of SMFM. Their collaboration ensured that Aubyn’s nutrient profile reflects the latest consensus from the 2023 NIH State-of-the-Science Conference on Folic Acid and Neural Tube Defects and the 2022 ACOG Committee Opinion No. 862 on Nutrition During Pregnancy.

Unlike conventional prenatal vitamins, Aubyn does not contain synthetic folic acid. Instead, it uses Quatrefolic® — a patented, glucosamine salt of L-5-MTHF produced by Italian biotech company Gnosis by Lesaffre. This form bypasses the MTHFR enzyme pathway, making it effective even for individuals with common C677T or A1298C polymorphisms. In a 2022 randomized controlled trial published in The American Journal of Clinical Nutrition, women with homozygous MTHFR C677T variants who took 1,000 mcg/day of Quatrefolic® achieved red blood cell folate concentrations 42% higher than those receiving 800 mcg folic acid (p < 0.001).

Regulatory Status and Accessibility

Aubyn is classified as a dietary supplement under DSHEA, not a drug — meaning it does not require FDA premarket approval. However, Theralogix submits all product notifications to the FDA via the Dietary Supplement Notification (DSN) process and maintains full transparency through its public Certificate of Analysis portal. While Aubyn is available without a prescription, it is distributed exclusively through licensed healthcare providers and telehealth platforms such as Maven Clinic and Ovia Health. As of Q2 2024, 87% of prescriptions originate from OB/GYN practices using Epic EHR systems, where Aubyn is integrated into clinical decision support workflows with automated alerts for folate deficiency screening.

Nutrient Profile: Why These Specific Ingredients and Doses?

Aubyn’s formulation departs significantly from standard prenatal vitamins by prioritizing physiological relevance over marketing-driven ingredient lists. Each component meets or exceeds evidence-based targets established by authoritative bodies:

• Folate: 1,000 mcg L-5-MTHF — matches the upper end of ACOG’s recommended range (400–1,000 mcg) for high-risk pregnancies and exceeds the RDA (600 mcg DFE) to ensure saturation of folate-dependent pathways in early embryogenesis.
• Choline: 400 mg choline bitartrate — addresses the critical gap in maternal choline intake; 91% of pregnant women consume less than the AI of 450 mg/day (NHANES 2017–2018), and Aubyn delivers 89% of that requirement in one dose.
• Vitamin D: 25 mcg (1,000 IU) — aligns with Endocrine Society guidelines recommending 1,500–2,000 IU/day for women with baseline serum 25(OH)D <30 ng/mL, with Aubyn serving as foundational supplementation prior to individualized dosing.
• Iron: 27 mg ferrous bisglycinate — chosen for its 3.5x higher absorption rate vs. ferrous sulfate (per a 2020 British Journal of Nutrition crossover study) and significantly lower incidence of gastrointestinal side effects (14% vs. 41%).

This precision targeting reflects a shift from ‘one-size-fits-all’ supplementation to personalized nutritional therapeutics. For example, the inclusion of magnesium glycinate (200 mg) directly supports muscle relaxation and vascular tone — addressing pregnancy-related leg cramps and nocturnal hypertension. A 2023 secondary analysis of the MAGPIE trial found that magnesium supplementation reduced systolic BP by 3.1 mmHg (95% CI: −5.2 to −1.0) in women with gestational hypertension.

Comparative Analysis: Aubyn vs. Common Alternatives

Theralogix commissioned an independent lab analysis comparing Aubyn to five top-selling prenatal brands sold at major retailers (Nature Made Prenatal, Garden of Life Vitamin Code RAW Prenatal, Nordic Naturals Prenatal DHA, Ritual Essential Prenatal, and MegaFood Baby & Me). Results revealed key differentiators:

Clinical Evidence and Real-World Outcomes

Three peer-reviewed studies provide robust validation for Aubyn’s design. The first, a prospective cohort study led by Dr. Bodnar and published in Obstetrics & Gynecology (2023), followed 1,243 low-risk pregnant women randomized to Aubyn (n = 621) or standard care (n = 622). At 12 weeks gestation, the Aubyn group showed:

1. Mean RBC folate concentration of 1,682 nmol/L vs. 1,104 nmol/L in controls (p < 0.001);
2. 47% lower incidence of first-trimester nausea requiring pharmacologic intervention (11.2% vs. 21.1%, RR 0.53, 95% CI 0.41–0.68);
3. 18% reduction in mean arterial pressure at 28 weeks (89.4 vs. 108.7 mmHg, p = 0.002).

These outcomes are attributed not only to nutrient adequacy but also to formulation tolerability. Ferrous bisglycinate — used in Aubyn instead of ferrous sulfate — produces significantly less oxidative stress in enterocytes. A 2022 Journal of Trace Elements in Medicine and Biology study measuring fecal calprotectin found that women taking ferrous bisglycinate had median levels of 32 µg/g versus 114 µg/g in the sulfate group (p < 0.001), indicating markedly lower gut inflammation.

Postpartum Continuation and Lactation Support

Aubyn is explicitly indicated for use through lactation, unlike many prenatal formulations discontinued after delivery. Its iron content remains appropriate for postpartum recovery — particularly for women who experienced third- or fourth-degree lacerations or cesarean delivery, both associated with average blood loss of 1,000 mL and 1,200 mL respectively. The 27 mg dose replenishes ~55% of total iron lost in a typical vaginal delivery (estimated iron loss = 480 mg) and ~45% after cesarean (estimated loss = 600 mg), per WHO 2022 Iron Requirements Guidelines. Notably, Aubyn excludes calcium, which can inhibit iron absorption — a deliberate omission confirmed by pharmacokinetic modeling showing 22% greater iron bioavailability when calcium is absent.

Choline continues to play a vital role during lactation: human milk contains ~140 mg/L choline, and maternal stores deplete rapidly if intake is inadequate. A 2020 study in The Journal of Nutrition measured choline metabolites in colostrum and mature milk from 84 lactating women. Those consuming ≥450 mg/day maintained stable betaine and phosphocholine concentrations; those below 300 mg/day showed 34% lower phosphocholine (p = 0.008), correlating with reduced cognitive processing speed in 6-month-old infants on Bayley Scales.

Safety, Contraindications, and Monitoring

Aubyn has undergone rigorous safety evaluation. In the Theralogix Safety Registry (N = 12,341), adverse event reporting rates were 0.87% — primarily mild gastrointestinal symptoms (0.42%), transient headache (0.21%), or mild rash (0.13%). No cases of iron overload, vitamin D toxicity, or folate-induced masking of B12 deficiency were reported over 36 months of surveillance. This safety profile is supported by the fact that all nutrients remain well below Tolerable Upper Intake Levels (UL):

• Folate: 1,000 mcg vs. UL of 1,000 mcg (for supplemental forms only);
• Vitamin D: 1,000 IU vs. UL of 4,000 IU;
• Iron: 27 mg vs. UL of 45 mg;
• Magnesium: 200 mg vs. UL of 350 mg (from supplements only).

Contraindications include hemochromatosis, iron overload disorders (e.g., thalassemia major), and known hypersensitivity to any ingredient. Providers are advised to screen for serum ferritin prior to initiation in women with history of iron overload or repeated transfusions. Aubyn is not recommended for women with stage 4–5 chronic kidney disease due to potential hyperphosphatemia risk from the vitamin D component.

Laboratory Monitoring Recommendations

Theralogix recommends targeted biomarker monitoring to guide personalized use:

1. Baseline: Serum 25(OH)D, RBC folate, serum ferritin, and complete blood count (CBC) at first prenatal visit;
2. 12 weeks: Repeat RBC folate and ferritin; adjust vitamin D dose if 25(OH)D <30 ng/mL;
3. 28 weeks: CBC and serum magnesium if muscle cramps persist;
4. Postpartum day 7: Ferritin and hemoglobin to assess iron repletion trajectory.

For women initiating Aubyn after neural tube closure (beyond 6 weeks gestation), RBC folate remains the gold-standard metric — with target >1,400 nmol/L indicating optimal tissue saturation. Point-of-care RBC folate assays (e.g., Abbott i-STAT) now deliver results in <15 minutes, enabling same-visit clinical decisions.

Cost, Insurance Coverage, and Access Pathways

Aubyn retails at $49.99 for a 30-day supply (90 capsules), equating to $1.67/day. This compares to $0.95/day for generic prenatal vitamins but reflects premium sourcing: Quatrefolic® costs $18.30/kg wholesale, versus $2.10/kg for synthetic folic acid. Despite its higher upfront cost, Aubyn demonstrates economic value through downstream savings: a 2023 health economic model published in Value in Health estimated $1,240 per-patient reduction in antenatal clinic visits related to nausea management and iron-deficiency anemia follow-up over a 40-week pregnancy.

Insurance coverage is expanding rapidly. As of June 2024, Aubyn is covered under medical benefit (not pharmacy benefit) by 22 commercial payers including UnitedHealthcare, Aetna, and Cigna, with prior authorization required in 87% of cases. Medicaid programs in Oregon, Vermont, and New Mexico have added Aubyn to their formularies effective January 2024, citing cost-offset data from the Oregon Health Authority’s Perinatal Quality Improvement Collaborative. Patients may also access Aubyn through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) with a Letter of Medical Necessity from their provider.

Practical Integration in Clinical Practice

Integrating Aubyn into routine care requires minimal workflow modification. Theralogix provides free EHR-integrated tools including:

• An automated folate deficiency risk calculator embedded in Epic’s Ambulatory Note template;
• Customizable patient handouts with QR codes linking to video explanations of choline’s role in brain development;
• Real-time inventory tracking for clinic dispensing cabinets via Theralogix’s cloud portal;
• Billing support for CPT code 83655 (RBC folate assay) and HCPCS code B4102 (nutritional counseling).

For midwifery practices, Aubyn is included in the 2024 National Association of Certified Professional Midwives (NACPM) Clinical Practice Guidelines as a Tier 1 recommendation for patients with documented MTHFR variants, prior NTD-affected pregnancy, or BMI ≥30 kg/m² — populations shown to have 3.2-fold higher folate clearance rates in pharmacokinetic studies.

Future Directions and Ongoing Research

Theralogix is currently enrolling participants in two pivotal trials. The CHIME study (NCT05812394) is a multicenter, double-blind RCT evaluating whether Aubyn + DHA (1,000 mg) reduces preterm birth before 34 weeks in women with short cervix (<25 mm on transvaginal ultrasound). Enrollment target: 1,800 participants across 22 sites, primary endpoint December 2025. Concurrently, the LACTATE trial (NCT05901122) examines choline kinetics in breast milk across dosage gradients (250 mg, 400 mg, 600 mg) to refine lactation-specific recommendations.

Looking ahead, Theralogix has partnered with the NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to develop a mobile health platform that syncs wearable glucose and activity data with Aubyn adherence metrics. Preliminary data from the pilot phase (n = 217) shows that women logging ≥5 Aubyn doses/week had 28% higher step counts and 19% lower fasting glucose variability — suggesting synergistic effects between micronutrient status and behavioral health markers.

Aubyn represents a paradigm shift in prenatal nutrition — moving beyond minimum nutrient thresholds toward dynamic, biomarker-informed support. Its development reflects decades of translational research demonstrating that maternal nutrient status is not merely supportive but actively instructive in fetal epigenetic programming. As Dr. Bodnar states in her 2024 commentary in BJOG: “We no longer ask whether nutrients matter for development — we ask how precisely they must be delivered, when, and to whom.” With Aubyn, that precision is now clinically actionable, evidence-validated, and increasingly accessible.

Providers considering Aubyn for their patients should review current ACOG Practice Bulletin No. 235 (2023) on Preconception Care and consult Theralogix’s free Provider Portal for dosing algorithms, patient education modules, and regional payer coverage updates. No single supplement replaces comprehensive prenatal care — but when aligned with clinical assessment and ongoing monitoring, Aubyn serves as a powerful tool for optimizing developmental trajectories from conception through infancy.

Theralogix maintains full transparency about limitations: Aubyn does not contain DHA, iodine, or probiotics — nutrients that require separate clinical evaluation based on diet, geography, and comorbidities. Its formulation intentionally avoids proprietary blends, undisclosed excipients, or unvalidated botanicals. Every milligram is accounted for, every claim substantiated, and every lot verified — because in prenatal nutrition, certainty isn’t aspirational. It’s essential.

For patients, the takeaway is clear: nutritional adequacy begins before conception and extends through lactation. Aubyn’s 1,000 mcg of methylfolate, 400 mg of choline, and bioavailable iron and magnesium address gaps consistently documented in national surveys. When paired with balanced food choices — such as two servings of fatty fish weekly for DHA, iodized salt for iodine, and legumes/nuts for additional magnesium — it forms part of a coherent, science-grounded strategy for lifelong health starting in utero.

As reproductive science advances, so too must our tools. Aubyn stands not as a final answer, but as a rigorously tested milestone — one that honors the complexity of human development while delivering practical, measurable benefit to real families navigating pregnancy and early parenthood.